RBC Capital Initiates Coverage On Alpine Immune Sciences with Outperform Rating, Announces Price Target of $19
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza has initiated coverage on Alpine Immune Sciences (NASDAQ:ALPN) with an Outperform rating and a price target of $19.
October 05, 2023 | 9:56 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alpine Immune Sciences has received an Outperform rating from RBC Capital, with a price target of $19.
The Outperform rating from RBC Capital indicates a positive outlook for Alpine Immune Sciences. This could potentially attract more investors, driving the stock price up in the short term. The price target of $19 also suggests that the analyst sees significant upside potential for the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100